Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers

NCT00967694
View directory record Official record
Conditions
Glaucoma, Sedation
Interventions
Nitrous oxide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Not applicable Interventional

An mHealth Mobile Application Supporting Maintenance of Physical Activity Among Men and Women With High Blood Pressure

NCT03937674
View directory record Official record
Conditions
Physical Activity
Interventions
HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Unmet Social Needs Study

NCT04977583
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Diabetes Mellitus, Hyperlipidemia
Interventions
Unmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 16, 2026, 5:57 AM EDT
Completed No phase listed Observational

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

NCT02576002
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Assigned pulmonary hypertension medication
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 16, 2026, 5:57 AM EDT
Enrolling by invitation Not applicable Interventional

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

NCT06052072
View directory record Official record
Conditions
Group 2 Pulmonary Hypertension, Heart Failure
Interventions
Gradient Denervation System
Device
Lead sponsor
Gradient Denervation Technologies
Industry
Eligibility
22 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Completed No phase listed Observational

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

NCT05776225
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Right heart catheterization (RHC)
Procedure
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • Hartford, Connecticut • Lakeland, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 16, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 16, 2026, 5:57 AM EDT
Recruiting Phase 4 Interventional

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221
View directory record Official record
Conditions
Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
Device · Drug
Lead sponsor
Jonathon Myers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Not applicable Interventional

A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions

NCT04382521
View directory record Official record
Conditions
Hyperlipemia, Hypertension, Type2 Diabetes
Interventions
Text Message Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 16, 2026, 5:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

NCT00803387
View directory record Official record
Conditions
Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions
Travaprost without BAC (Travatan Z)
Drug
Lead sponsor
United States Air Force
Federal
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2008 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Not applicable Interventional

Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy

NCT04119232
View directory record Official record
Conditions
Hypertension in Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Social incentives-based program
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 16, 2026, 5:57 AM EDT
Completed No phase listed Observational

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

NCT01729611
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
17 Years to 90 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 16, 2026, 5:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

NCT05961384
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 16, 2026, 5:57 AM EDT
Terminated No phase listed Observational

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

NCT00706082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Angiogenic Imaging in Pulmonary Arterial Hypertension

NCT03166306
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
Interventions
PET-CT Imaging with [89Zr]-bevacizumab
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 16, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 16, 2026, 5:57 AM EDT